Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSV-tK + Valacyclovir Gene Therapy With Radiotherapy and Chemotherapy for Newly Diagnosed AA and GBM
NCT03603405Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Feb 2018
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aglatimagene besadenovec in glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), sponsored by Houston Methodist Research Institute. Primary endpoint: Overall Survival at 60 months. Started Feb 2018; status: recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT03603405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603405.